Skip to main content
SpringerLink
Log in

Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options

  • Lymphomas (PA Hamlin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complication that occurs at a rate of approximately 3 % a year for the first 10 years of observation. Transformation is accompanied by increased risk of refractoriness and a poor expectation of survival. Genetic and epigenetic triggers for transformation have been described. Prior to routine use of rituximab, transformed lymphoma was managed in a fashion similar to that for de novo diffuse large B-cell lymphoma, with generally poor results. Rituximab appears to have improved outcomes. Some centres, including our own, use high-dose chemotherapy with stem cell transplantation as consolidation for those with responsive disease. Here, we focus on transformed follicular lymphoma, and provide an overview of the current literature and our approach to management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311(23):1471–5.

    Article  PubMed  CAS  Google Scholar 

  2. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165–9.

    Article  PubMed  Google Scholar 

  3. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–94.

    PubMed  CAS  Google Scholar 

  4. Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157(2):188-96.

    Google Scholar 

  5. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–33.

    Article  PubMed  Google Scholar 

  6. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983;52(3):393–8.

    Article  PubMed  CAS  Google Scholar 

  7. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21):4643–51.

    Article  PubMed  Google Scholar 

  8. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93(3):471–2.

    Article  PubMed  Google Scholar 

  9. • Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20(3):508-12. Described the utility of standardised uptake values in identifying transformed lymphoma.

    Article  PubMed  CAS  Google Scholar 

  10. Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17(10):1539–45.

    Article  PubMed  Google Scholar 

  11. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–22.

    Article  PubMed  CAS  Google Scholar 

  12. Sinha R, Byrtek M, De Joubner N, Nooka A, Taylor M, Cerhan J, et al. Examining the outcomes of watchful waiting among US patients with advanced stage follicular lymphoma [abstract 775]. American Society of Haematology Conference 2011.

  13. Cohen Y, Da'as N, Libster D, Amir G, Berrebi A, Polliack A. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol. 2002;68(2):80–3.

    Article  PubMed  CAS  Google Scholar 

  14. Matolcsy A, Schattner EJ, Knowles DM, Casali P. Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol. 1999;29(4):1253–64.

    Article  PubMed  CAS  Google Scholar 

  15. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica. 2006;91(10):1405–9.

    PubMed  CAS  Google Scholar 

  16. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136(2):286–93.

    Article  PubMed  CAS  Google Scholar 

  17. Gentles AJ, Alizadeh AA, Lee S-I, Myklebust JH, Shachaf CM, Shahbaba B, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114(15):3158–66.

    Article  PubMed  CAS  Google Scholar 

  18. Symmans WF, Katz RL, Ordoñez NG, Dalton H, Romaguera JE, Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol. 1995;39(4):673–82.

    PubMed  CAS  Google Scholar 

  19. Szereday Z, Csernus B, Nagy M, László T, Warnke RA, Matolcsy A. Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol. 2000;156(3):1017–24.

    Article  PubMed  CAS  Google Scholar 

  20. Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553–7.

    Article  PubMed  CAS  Google Scholar 

  21. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116(9):1489–97.

    Article  PubMed  CAS  Google Scholar 

  22. Martinez A, Carreras J, Campo E. The follicular lymphoma microenvironment: from tumor cell to host immunity. Curr Hematol Malignancy Rep. 2008;3(4):179–86.

    Article  Google Scholar 

  23. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25(4):390–8.

    Article  PubMed  CAS  Google Scholar 

  24. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957–64.

    Article  PubMed  CAS  Google Scholar 

  25. Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41(8):873–5.

    Article  PubMed  CAS  Google Scholar 

  26. Akers NK, Curry JD, Conde L, Bracci PM, Smith MT, Skibola CF. Association of HLA-DQB1 alleles with risk of follicular lymphoma. Leuk Lymphoma. 2011;52(1):53–8.

    Article  PubMed  CAS  Google Scholar 

  27. Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, et al. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood. 2011;117(11):3147–50.

    Article  PubMed  CAS  Google Scholar 

  28. Al-Tourah AJ, Savage KJ, Gill KK, Klasa RJ, Sehn LH, Shenkier TN, et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annu Meet Abstr. 2007;110(11):790.

    Google Scholar 

  29. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3793–803.

    PubMed  CAS  Google Scholar 

  30. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–81.

    PubMed  CAS  Google Scholar 

  31. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(10):2453–63.

    Article  PubMed  CAS  Google Scholar 

  32. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19(19):3918–28.

    PubMed  CAS  Google Scholar 

  33. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23(30):7565–73.

    Article  PubMed  CAS  Google Scholar 

  34. Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant. 2005;36(11):955–61.

    Article  PubMed  CAS  Google Scholar 

  35. Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol. 2001;113(1):202–8.

    Article  PubMed  CAS  Google Scholar 

  36. •• Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol. 2011;152(5):600-10. The only prospective study of high dose chemotherapy with ASCT in transformed lymphoma.

    Article  PubMed  CAS  Google Scholar 

  37. Hamadani M, Benson DM, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008;81(6):425–31.

    Article  PubMed  Google Scholar 

  38. Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant. 2007;13(8):956–64.

    Article  PubMed  Google Scholar 

  39. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19(3):727–35.

    PubMed  CAS  Google Scholar 

  40. Villa KS D, Crump M, Toze C, Rubinger M, Lee C, Alzahrani M, et al. “Focus on…” session: high-dose chemotherapy. Ann Oncol. 2011;22 suppl 4:iv115–6.

    Google Scholar 

  41. • Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012;53(5):830-5. A retrospective analysis of ASCT in transformed lymphoma in patients previously exposed to rituximab.

    Article  PubMed  CAS  Google Scholar 

  42. Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant. 2008;42(9):601–8.

    Article  PubMed  CAS  Google Scholar 

  43. Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon P-A, Traverse-Glehen A, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234–41.

    Article  PubMed  Google Scholar 

  44. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223–30.

    Article  PubMed  Google Scholar 

  45. Villa. Lugano ASCT transformed lymphoma. Ann Oncol. 2011;22(Supplement 4):iv10–24.

    Article  Google Scholar 

  46. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211–7.

    Article  PubMed  Google Scholar 

  47. Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(8):1502–8.

    Article  PubMed  Google Scholar 

  48. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2009;15(5):547–53.

    Article  PubMed  Google Scholar 

  49. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and maintenance improves progression free survival but not overall survival in patients with relapsed or resistant follicular lymphoma prior receiving an autologous transplant. ASH Annu Meet Abstr. 2010;116(21):3567.

    Google Scholar 

  50. Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011;154(4):477–81.

    Article  PubMed  CAS  Google Scholar 

  51. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

    Eric Wong & Michael Dickinson

  2. University of Melbourne, Parkville, VIC, Australia

    Michael Dickinson

Authors
  1. Eric Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Dickinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Dickinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, E., Dickinson, M. Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options. Curr Oncol Rep 14, 424–432 (2012). https://doi.org/10.1007/s11912-012-0258-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0258-4

Keywords

Search

Navigation